Skip to main content
NACFC 2025 Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Presentation Icons
Livestreamed Session
Livestreamed Session

Workshop

W20--Cutting-edge Clinical Trials: Insights & Updates

W20.2- A Phase II study (CLAIRAFLY®) evaluating safety, tolerability, pharmacokinetics and pharmacodynamics of the DPP1 (CatC) inhibitor BI 1291583 in cystic fibrosis: Effects of CFTR modulator therapy use

Friday, October 24, 2025
10:15 AM - 12:15 PM PDT
Location: Flex A